Staphylococcus aureus: Role and impact in the treatment of nosocomial pneumonia;Staphylococcus aureus: Place et impact dans la prise en charge des pneumopathies nosocomiales

Revue des Maladies Respiratoires

Volumn 22, Issue 4, 2005, Pages 595-603

  Benhamou, D ^a   Carrie A S ^a   Lecomte, F ^a  

^a Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

Author keywords

Antibiotics; Methicillin resistance; Nosocomial pneumonia; Staphylococcal pneumonia; Staphylococcus aureus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CLOXACILLIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; FOSFOMYCIN; FUSIDIC ACID; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; METICILLIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTERIAL PNEUMONIA; BLOOD TOXICITY; CLINICAL FEATURE; COMA; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; EMPIRICAL RESEARCH; FRANCE; GASTROINTESTINAL TOXICITY; GRAM NEGATIVE INFECTION; HEAD INJURY; HOSPITAL INFECTION; HUMAN; INHALATION; KIDNEY DISEASE; LIVER DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; OROPHARYNX; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PROGNOSIS; PSEUDOMEMBRANOUS COLITIS; REVIEW; RISK FACTOR; SKIN ALLERGY; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; VESTIBULOCOCHLEAR NERVE DISEASE;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; FRANCE; HUMANS; METHICILLIN RESISTANCE; PNEUMONIA, STAPHYLOCOCCAL; PROGNOSIS; STAPHYLOCOCCUS AUREUS;

EID: 25844482665     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1019/200530051     Document Type: Review

References (45)

1. Ibelings MM, Bruining HA: Methicillin-resistant staphylococcus aureus: Acquisition and risk of death in patients in the intensive care unit. Eur J Surg 1998; 164: 411-8.
2. Albertini MT, Berardi L, Berrouane Y: Surveillance of méthicillin resistant Staphylococcus aureus (mrsa) and enterobacteriaceae producing extended - spectrum betalactamase (esble) in northern france: A five year multicentre incidence study. J Hosp Infect 2002; 52: 107-13.
3. Combes A, Luyt CE, Fagon JY, Wollf M, Trouillet JL, Gibert C ACJ, for the Pneuma Trial Group: Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004; 170: 787-92.
4. CCLIN Paris-Nord. Surveillance des BMR à partir du laboratoire dans les hôpitaux de l'inter-région Paris-nord (hors ap-hp de Paris). Résultats de l'enquête menée en 2002. Mai 2003. Disponible sur http://www.Ccr.Jussieu.Fr/cclin/bmr/bmr.html. 2003.
5. Gastmeier P, Sohr D, Geffers C, Nassauer A, Dettenkofer M, Ruden H: Occurrence of methicillin-resistant Staphylococcus aureus infections in german intensive care units. Infection 2002; 30: 198-202.
6. Richards MJ, Edwards JR, Culver DH, Gaynes RP: Nosocomial infections in medical intensive care units in the united states. Critical Care Medicine 1999; 27: 887-92.
7. George DL, Falk PS, Wunderink RG, Leeper KV, Jr, Meduri GU, Steere EL, Cor-Bett CE, Mayhall CG: Epidemiology of ventilator-acquired pneumonia. Based on protected bronchoscopic sampling. Am J Respir Crit Care Med 1998; 158: 1839-47.
8. Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH: Epidemiology and outcomes of ventilator-associated pneumonia in a large us database. Chest 2002; 122: 2115-21.
9. Chastre J, Fagon JY: Ventilator associated pneumonia. Am J Respir Crit Care Med 2002; 165: 860-903.
10. Gastmeier P, Geffers C, Sohr D, Schwab F, Behnke M, Ruden H: Surveillance of nosocomial infections in intensive care units. Current data and interpretations. Wien Klin Wochenschr Feb 2003; 115: 99-103.
11. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piemont Y, Brousse N, Floret D, Etienne J: Association between Staphylococcus aureus strains carrying gene for panton-valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359: 753-9.
12. Saiman L, O'Keefe M, Graham PL, Wu F, Said-Salim B, Kreiswirth B, Lasala A, Schlievert PM, Della-Latta P: Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 2003; 37: 1313-9.
13. Campbell W, Hendrix E, Schwalbe R, Fattom A, Edelman R: Head-injured patients who are nasal carriers of Staphylococcus aureus are at high risk for Staphylococcus aureus pneumonia. Crit Care Med 1999; 27: 798-801.
14. Allaouchiche B, Meugnier H, Freney J, Fleurette J, Motin J: Rapid identification of Staphylococcus aureus in bronchoalveolar lavage fluid using a DNA probe (accuprobe). Intensive Care Med 1996; 22: 683-7.
15. Pujol M, Corbella X, Pena C, Pallares R, Dorca J, Verdaguer R, Diaz-Prieto A, Ariza J, Gudiol F: Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: 622-8.
16. Watanakunakorn C: Bacteremic Staphylococcus aureus pneumonia. Scand J Infect Dis 1987; 19: 623-7.
17. Lentino JR, Hennein H, Krause S, Pappas S, Fuller G, Schaaff D, Dicostanzo MB: A comparison of pneumonia caused by gentamicin, methicillin-resistant and gentamicin, methicillin-sensitive Staphylococcus aureus: Epidemiologic and clinical studies. Infect Control 1985;6:267-72.
18. Espersen F, Gabrielsen J: Pneumonia due to Staphylococcus aureus during mechanical ventilation. J Infect Dis 1981; 144: 19-23.
19. Inglis TJ, Sproat LJ, Hawkey PM, Gibson JS: Staphylococcal pneumonia in ventilated patients: A twelve-month review of cases in an intensive care unit. J Hosp Infect 1993; 25: 207-10.
20. Sirvent JM, Torres A, El-Ebiary M, Castro P, Debatlle J, Bonet A: Protective effect of intravenously administered cefuroxime against nosocomial pneumonia in patients with structural coma. Am J Respir Crit Care Med 1997; 155: 1729-34.
21. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531-9.
22. Kolleff MH. Ventilator-associated pneumonia: A multivariate analysis. JAMA 1993; 270: 1965-70.
23. Weber SG GH, Hooper DC, Karchmer AW, Carmeli Y: Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415-22.
24. Manhold C, Von Rolbicki U, Erase R, Timm J, Von Pritzbuer E, Heimesaat M, Kljucar S: Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study. Intensive Care Med 1998; 24: 1327-30.
25. Franson TR, Hierholzer WJ Jr, Labrecque DR: Frequency and characteristics of hyperbilirubinemia associated with bacteremia. Rev Infect Dis 1985; 7: 1-9.
26. Hayon J, Figliolini C, Combes A, Trouillet JL, Kassis N, Dombret MC, Gibert C, Chastre J: Role of serial routine microbiologic culture results in the initial management of ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 41-6.
27. Timsit JF, Cheval C, Gachot B, Bruneel F, Wolff M, Carlet J, Regnier B: Usefulness of a strategy based on bronchoscopy with direct examination of bronchoalveolar lavage fluid in the initial antibiotic therapy of suspected ventilator-associated pneumonia. Intensive Care Med 2001; 27: 640-7.
28. Bodi M, Ardanuy C, Rello J: Impact of gram-positive resistance on outcome of nosocomial pneumonia. Crit Care Med 2001; 29: N82-6.
29. CCLIN Paris-Nord: Surveillance des BMR à partir du laboratoire dans les hôpitaux de l'inter-région Paris-nord (hors ap-hp de Paris). Résultats de l'enquête menée en 2003. Juillet 2004. Disponible sur http://www.Ccr.Jussieu.Fr/cclin/bmr/bmr.Html. 2004.
30. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistant staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
31. Sieradzki K, Roberts RB, Haber SW, Tomasz A: The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340: 517-23.
32. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR: Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493-501.
33. Briskier A: Antibiotiques, agents anti-bactériens et antifongiques. Vancomycine, teicoplamine. Elypse 1999: 931-34
34. Wysocki M, Delatour F, Faurisson F, Rauss a, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D: Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: Prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
35. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S; Pneuma Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for ventilator- associated pneumonia in adults: A randomized trial. JAMA 2003; 290: 2588-98.
36. Fagon JY, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, Falcone RE, Anholm JD, Paganin F, Fabian TC, Lilienthal F, and the Nosocomial Pneumonia Group: Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000; 161: 753-62.
37. Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group. Linezolid (pnu-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-12.
38. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B: Linezolid versus vancomycin for the treatment of methicillin-resistant staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-90.
39. Meka VG, Gold HS: Antimicrobial resistance to linezolid. Clinical Infectious Diseases 2004; 39: 1010-5.
40. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-85.
41. Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
42. Lee SC, Hua CC, Yu TJ, Shieh WB, See LC: Risk factors of mortality for nosocomial pneumonia: Importance of initial anti-microbial therapy. Int J Clin Pract 2005; 59: 39-45.
43. Cooper BS, Stone SP, Kibbler CC, Cookson BD, Roberts JA, Medley GF, Duckworth G, Lai R, Ebrahim S: Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (mrsa): Systematic review of the literature. BMJ 2004; 329: 533-9.
44. Lucet JC, Rigaud MP, Mentre F, Kassis N, Deblangy C, Andremont A, Bouvet E: Hand contamination before and after different hand hygiene techniques: A randomized clinical trial. J Hosp Infect 2002; 50: 276-80.
45. Fagon Jy CJ, Vuagnat A, Trouillet JL, Novara A, Gibert C: Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996; 275: 866-9.